retatrutide news Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS investigation π¨Breaking: Retatrutide's first Phase 3
Description
A higher proportion of the hormone therapy users achieved the weight loss that they were aiming for within one year
A 2024 study in The BMJ examined infant outcomes related to GLP-1 exposure in early pregnancy

Our team of experienced providers is supervised by Dr

Slower titration was the main lever for adherence
Furthermore, a review of the FDA Adverse Event Reporting System (FAERS) data lists allodynia among the top 50 adverse reactions reported with tirzepatide

"Normal" eating on GLP-1 is eating smarter , not eating the same way with less appetite
